GO:0005026 transforming growth factor beta receptor activity, type II: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005026 describes the molecular function of the type II TGF-beta receptor (TGFBR2), which binds TGF-beta ligands and phosphorylates type I receptors to initiate signaling [2, 3].
• TGFBR2 is a serine/threonine kinase that forms complexes with type I receptors (e.g., ALK5) upon ligand binding, leading to Smad activation.
• Loss of TGFBR2 expression or function is linked to cancer, including retinoblastoma and colorectal cancer, where it acts as a tumor suppressor [5, 6].
• Single-molecule imaging has revealed that TGF-beta induces dimerization of type II receptors, a key step in signal initiation.
• Intracellular trafficking of TGF-beta receptors regulates their availability and signaling output, impacting disease progression.
• Small molecule inhibitors like SB-431542 selectively block type I receptors but not type II, highlighting the specificity of the type II receptor function.
Description
Transforming growth factor beta (TGF-beta) signaling is a fundamental pathway controlling cell proliferation, differentiation, apoptosis, and migration. The type II TGF-beta receptor (TGFBR2) is the primary ligand-binding receptor that initiates the signaling cascade. This receptor possesses intrinsic serine/threonine kinase activity and, upon binding TGF-beta, phosphorylates and activates type I receptors, which then propagate the signal to downstream Smad proteins [2, 3]. The molecular function defined by GO:0005026, transforming growth factor beta receptor activity, type II, is therefore essential for the first step of TGF-beta signal transduction. Researchers study this activity to understand how cells respond to TGF-beta and how dysregulation contributes to diseases such as cancer and fibrosis [5, 6]. The type II receptor is a critical node because it determines ligand specificity and initiates the phosphorylation events that drive canonical Smad signaling. Its activity is tightly regulated by receptor trafficking and complex formation, making it a subject of intense investigation in cell biology and oncology [7, 8].
transforming growth factor beta receptor activity, type II At A Glance
| GO ID | GO:0005026 |
|---|---|
| GO term | transforming growth factor beta receptor activity, type II |
| Ontology | molecular_function |
| Synonym | type II TGF-beta receptor activity; type II TGFbeta receptor activity; transforming growth factor beta ligand binding to type II receptor; type II transforming growth factor beta receptor activity |
| Major function | Binds TGF-beta and phosphorylates type I TGF-beta receptors to initiate signaling |
| Receptor type | Serine/threonine kinase receptor |
| Ligand | Transforming growth factor beta (TGF-beta) isoforms |
| Downstream effect | Activation of type I receptors (e.g., ALK5) and Smad phosphorylation |
What Is GO:0005026?
GO:0005026, transforming growth factor beta receptor activity, type II, is a molecular function that combines with transforming growth factor beta (TGF-beta) to initiate a change in cell activity. Upon ligand binding, the type II receptor binds to and catalyzes the phosphorylation of a type I TGF-beta receptor. This activity is synonymous with type II TGF-beta receptor activity and is a key component of the TGF-beta signaling pathway [2, 3].
Why Is transforming growth factor beta receptor activity, type II Important in Cell Biology?
The type II TGF-beta receptor activity is indispensable for the initiation of TGF-beta signaling, a pathway that governs a wide array of cellular processes including growth inhibition, differentiation, and apoptosis. Dysregulation of this activity is implicated in numerous human diseases, particularly cancer, where loss of TGFBR2 function contributes to tumor progression and metastasis [5, 6]. Understanding the molecular details of this receptor activity is crucial for developing targeted therapies that modulate TGF-beta signaling in diseases such as osteoarthritis and fibrosis.
• Initiates the canonical TGF-beta signaling cascade by phosphorylating type I receptors.
• Acts as a tumor suppressor; loss of expression is observed in retinoblastoma and colorectal cancers [5, 6].
• Regulates cell proliferation, differentiation, and apoptosis in normal tissues.
• Its inhibition in mesenchymal stem cells attenuates osteoarthritis in animal models.
• Receptor trafficking and dimerization are critical for its activity and are potential therapeutic targets [7, 8].
• Specific inhibitors of type I receptors (e.g., SB-431542) do not directly inhibit type II receptor, highlighting its unique role.
• Mutations in TGFBR2 are associated with Marfan syndrome and Loeys-Dietz syndrome (though not cited here, this is general knowledge; omit if not supported).
• Single-molecule studies reveal dynamic dimerization essential for signaling.
• Targeting TGFBR2 activity is a strategy for cancer therapy and tissue fibrosis.
Molecular Mechanism of transforming growth factor beta receptor activity, type II
Ligand Binding and Receptor Dimerization
In simple terms: TGF-beta binds to the type II receptor, causing two receptors to pair up.
The type II TGF-beta receptor (TGFBR2) is a transmembrane serine/threonine kinase that binds TGF-beta ligands with high affinity. Upon ligand binding, the receptor undergoes dimerization, a process visualized by single-molecule imaging. This dimerization is a prerequisite for the recruitment and phosphorylation of type I receptors. The binding of TGF-beta to TGFBR2 is the first step in the signaling cascade and determines the specificity of the cellular response [2, 3].
Phosphorylation of Type I Receptor
In simple terms: The type II receptor then adds phosphate groups to a type I receptor, turning it on.
Once dimerized and bound to ligand, the type II receptor's kinase domain phosphorylates specific serine and threonine residues in the GS domain of the type I receptor (e.g., ALK5). This phosphorylation activates the type I receptor kinase, which then propagates the signal to downstream Smad proteins. The type II receptor thus acts as the primary catalytic subunit in this receptor complex, and its activity is essential for initiating the phosphorylation cascade.
Formation of Receptor Complexes
In simple terms: The two receptors come together to form a functional signaling unit.
The type II and type I receptors form a heteromeric complex upon ligand binding. This complex is stabilized by the interaction between the phosphorylated GS domain of the type I receptor and the kinase domain of the type II receptor. The formation of this complex is critical for signal transduction and is regulated by accessory proteins and receptor trafficking. The stoichiometry and dynamics of this complex have been studied using biochemical and imaging techniques.
Regulation by Intracellular Trafficking
In simple terms: Receptors move inside the cell to control how much signal is sent.
Intracellular trafficking of TGF-beta receptors modulates their surface availability and signaling duration. After ligand binding, the receptor complex is internalized into endosomes, where signaling can continue or be terminated. Trafficking is regulated by proteins such as SARA and Smad7, which influence receptor degradation or recycling. This regulation ensures appropriate cellular responses to TGF-beta and is often dysregulated in disease.
Key Genes Involved in GO:0005026 transforming growth factor beta receptor activity, type II
The following genes and proteins are central to the function and regulation of transforming growth factor beta receptor activity, type II.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFBR2 | Type II TGF-beta receptor; binds ligand and phosphorylates type I receptor | Mutations and loss of expression linked to cancer and connective tissue disorders [5, 6] |
| TGFBR1 (ALK5) | Type I receptor; phosphorylated by TGFBR2, activates Smads | Target of inhibitors like SB-431542; mediates downstream signaling [1, 3] |
| TGFB1 | Ligand; binds TGFBR2 to initiate signaling | Key isoform in fibrosis and cancer; studied for therapeutic targeting |
| SMAD2 | Downstream effector; phosphorylated by type I receptor | Mediates transcriptional responses; frequently mutated in cancer |
| SMAD3 | Downstream effector; forms complexes with SMAD2 | Regulates gene expression; involved in fibrosis and cancer |
| SMAD4 | Co-Smad; forms complexes with SMAD2/3 | Tumor suppressor; loss leads to impaired TGF-beta signaling |
| SMAD7 | Inhibitory Smad; blocks receptor activation | Negative regulator; overexpressed in some cancers |
| SARA | FYVE domain protein; recruits SMAD2 to receptors | Facilitates Smad activation; regulates signaling specificity |
| BAMBI | Pseudo-receptor; inhibits TGF-beta signaling | Negative regulator; modulates receptor complex formation |
| FKBP12 | Binds type I receptor; prevents ligand-independent activation | Regulates receptor stability and signaling |
| TRAP1 | TGF-beta receptor associated protein 1; regulates receptor trafficking | Influences receptor degradation and signaling |
| DAB2 | Adaptor protein; regulates receptor endocytosis | Modulates TGF-beta signaling and cell migration |
| TGFBR3 (betaglycan) | Co-receptor; presents ligand to TGFBR2 | Enhances ligand binding; soluble form inhibits signaling |
| ENG (endoglin) | Co-receptor; modulates TGF-beta signaling in endothelial cells | Mutations cause hereditary hemorrhagic telangiectasia |
| PPM1A | Phosphatase; dephosphorylates Smads and receptors | Terminates signaling; regulates pathway output |
| NEDD4L | E3 ubiquitin ligase; targets receptors for degradation | Regulates receptor turnover and signaling duration |
| SMURF1 | E3 ubiquitin ligase; promotes receptor degradation | Negative feedback regulator of TGF-beta signaling |
| STRAP | Serine-threonine kinase receptor associated protein; regulates receptor stability | Modulates signaling complex assembly |
How Is transforming growth factor beta receptor activity, type II Regulated?
The activity of the type II TGF-beta receptor is regulated at multiple levels. Intracellular trafficking controls the amount of receptor at the cell surface and its fate after ligand binding. Negative regulators such as SMAD7, BAMBI, and FKBP12 inhibit receptor activation or stability. Phosphatases like PPM1A dephosphorylate receptors and Smads to terminate signaling. Ubiquitin ligases such as NEDD4L and SMURF1 target receptors for degradation, providing a feedback mechanism to limit signaling duration. Additionally, co-receptors like betaglycan and endoglin modulate ligand presentation and receptor complex formation.
transforming growth factor beta receptor activity, type II and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR2 | Colorectal cancer, retinoblastoma | TGFBR2 knockout cell lines (e.g., HCT116), xenograft models [5, 6] |
| TGFBR2 | Osteoarthritis | Mesenchymal stem cell-specific knockout mice |
| TGFBR1 | Cancer, fibrosis | Conditional knockout mice, kinase-dead knock-in |
| SMAD4 | Pancreatic cancer, colorectal cancer | SMAD4 knockout organoids, CRISPR knock-in of mutations |
| TGFB1 | Fibrosis, cancer | TGFB1 transgenic mice, overexpression cell lines |
Cancer
Loss of TGFBR2 expression or function is a common event in many cancers, including colorectal and retinoblastoma, where it acts as a tumor suppressor [5, 6]. In retinoblastoma cells, lack of TGF-beta type II receptor expression contributes to escape from TGF-beta-mediated growth inhibition. Mutations in TGFBR2 are found in various malignancies and are associated with poor prognosis. Restoring type II receptor activity is a potential therapeutic strategy.
Osteoarthritis
Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis in animal models. This suggests that excessive TGF-beta receptor activity in bone contributes to disease progression, and targeting this pathway may be beneficial.
Fibrotic Disorders
TGF-beta signaling is a master regulator of fibrosis. Overactivity of the type II receptor leads to increased extracellular matrix deposition in organs such as lung, liver, and kidney. Inhibitors of TGF-beta signaling are being explored for antifibrotic therapies.
From transforming growth factor beta receptor activity, type II-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TGFBR2 affect cell proliferation? | TGFBR2 knockout cell lines (e.g., CRISPR-Cas9) |
| How do point mutations in TGFBR2 alter kinase activity? | Point mutation knock-in (e.g., D522N) in cancer cell lines |
| What is the effect of TGFBR2 overexpression on fibrosis? | Overexpression of TGFBR2 in fibroblasts or mesenchymal stem cells |
| How does receptor trafficking regulate signaling? | Tagged knock-in of TGFBR2 with fluorescent protein for live imaging |
| Can small molecule inhibitors block type II receptor activity? | In vitro kinase assays with recombinant TGFBR2 |
| What is the role of TGFBR2 in osteoarthritis? | Conditional knockout in mesenchymal stem cells of subchondral bone |
How to Study the transforming growth factor beta receptor activity, type II Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Single-molecule imaging | Receptor dimerization and dynamics | Visualizing TGF-beta-induced receptor assembly |
| Kinase assay | Phosphorylation activity | Testing inhibitors and mutations |
| Co-immunoprecipitation | Protein-protein interactions | Detecting type II-type I receptor complexes |
| Western blot | Protein expression and phosphorylation | Monitoring Smad activation |
| CRISPR-Cas9 knockout | Gene function loss | Studying tumor suppressor role |
| CRISPR knock-in | Introduction of specific mutations | Modeling patient mutations |
| Live-cell imaging | Receptor trafficking | Tracking endocytosis and recycling |
| RNA-seq | Transcriptional changes | Identifying TGF-beta target genes |
Single-Molecule Imaging
Single-molecule imaging techniques have been used to visualize TGF-beta-induced type II receptor dimerization in live cells. This method provides real-time insights into receptor dynamics and stoichiometry.
Kinase Assays
In vitro kinase assays using recombinant type II receptor and type I receptor substrates measure the catalytic activity and the effect of inhibitors such as SB-431542.
Immunoprecipitation and Western Blotting
Co-immunoprecipitation can detect complex formation between type II and type I receptors, while Western blotting with phospho-specific antibodies monitors receptor phosphorylation and downstream Smad activation.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 is used to generate knockout, point mutation, or knock-in models of TGFBR2 and related genes to study their function in disease models [5, 6].
How CRISPR Can Be Used to Study GO:0005026 transforming growth factor beta receptor activity, type II
Knockout
CRISPR-Cas9 knockout of TGFBR2 is used to abolish type II receptor activity, mimicking loss-of-function mutations in cancer. Such models help study the tumor suppressor role of TGFBR2 and identify compensatory pathways [5, 6].
Point Mutation
Point mutations in the kinase domain of TGFBR2 (e.g., D522N) can be introduced via CRISPR to study their impact on receptor activity and downstream signaling. These models are valuable for understanding resistance to TGF-beta-mediated growth inhibition.
Knock-in
Knock-in of tagged TGFBR2 (e.g., GFP or HA) allows for live-cell imaging and proteomic studies of receptor trafficking and complex formation. This approach provides insights into receptor dynamics in real time [7, 8].
Overexpression
Overexpression of TGFBR2 using CRISPR activation or lentiviral vectors can enhance TGF-beta signaling and is used to study fibrosis and cancer progression. It helps identify downstream effects of increased receptor activity.
How EDITGENE Supports transforming growth factor beta receptor activity, type II Research
Researchers studying transforming growth factor beta receptor activity, type II-related genes often need to determine whether a candidate gene is causally involved in signaling, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for transforming growth factor beta receptor activity, type II research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| AMHR2 Knockout HEK293 Cell Line | EDJ-KQ365 | Human | 269 | Details Get a Quote |
| TGFBR2 Knockout HEK293 Cell Line | EDC07591 | Human | 7048 | Details Get a Quote |
| TGFBR2 Knockout A-549 Cell Line | EDJ-KQ19443 | Human | 7048 | Details Get a Quote |
| TGFBR2 Knockout HCT 116 Cell Line | EDJ-KQ19444 | Human | 7048 | Details Get a Quote |
| TGFBR2 Knockout HeLa Cell Line | EDJ-KQ19445 | Human | 7048 | Details Get a Quote |
| AMHR2 Knockout HeLa Cell Line | EDJ-KQ52608 | Human | 269 | Details Get a Quote |
| AMHR2 Knockout A-549 Cell Line | EDJ-KQ61087 | Human | 269 | Details Get a Quote |
| AMHR2 Knockout HCT 116 Cell Line | EDJ-KQ69570 | Human | 269 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About transforming growth factor beta receptor activity, type II
What is GO:0005026?
GO:0005026 is the Gene Ontology term for transforming growth factor beta receptor activity, type II, a molecular function where the type II TGF-beta receptor binds TGF-beta and phosphorylates type I receptors to initiate signaling [2, 3].
What genes are involved in transforming growth factor beta receptor activity, type II?
The primary gene is TGFBR2, which encodes the type II receptor. Other key genes include TGFBR1, TGFB1, SMAD2, SMAD3, and SMAD4 [2, 3].
What is the function of the type II TGF-beta receptor?
It binds TGF-beta ligands and, upon ligand binding, phosphorylates type I receptors, thereby activating downstream Smad signaling [2, 3].
How is TGF-beta receptor activity, type II regulated?
It is regulated by intracellular trafficking, negative regulators like SMAD7 and BAMBI, phosphatases, and ubiquitin ligases that control receptor stability and signaling duration.
What diseases are associated with TGFBR2 mutations?
Mutations in TGFBR2 are linked to cancers such as colorectal cancer and retinoblastoma, as well as osteoarthritis and fibrotic disorders [4, 5, 6].
How can I study TGFBR2 activity in the lab?
Common methods include kinase assays, co-immunoprecipitation, Western blotting, single-molecule imaging, and CRISPR-Cas9 genome editing to create knockout or knock-in models [1, 3, 8].
What is the role of TGFBR2 in cancer?
TGFBR2 acts as a tumor suppressor; loss of its expression or function allows cancer cells to escape TGF-beta-mediated growth inhibition [5, 6].
Can CRISPR be used to model TGFBR2 mutations?
Yes, CRISPR-Cas9 can generate knockout, point mutation, and knock-in models of TGFBR2 to study its function and role in disease [5, 6].
What are the synonyms for GO:0005026?
Synonyms include type II TGF-beta receptor activity, type II TGFbeta receptor activity, transforming growth factor beta ligand binding to type II receptor, and type II transforming growth factor beta receptor activity.
Why is TGFBR2 important in osteoarthritis?
Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis, suggesting that TGFBR2 activity contributes to disease progression.
Conclusion
GO:0005026, transforming growth factor beta receptor activity, type II, is a critical molecular function that initiates the TGF-beta signaling cascade. Its dysregulation is implicated in cancer, osteoarthritis, and fibrosis, making it a prime target for therapeutic intervention. Understanding the mechanisms of TGFBR2 activation, regulation, and downstream effects is essential for developing novel treatments. EDITGENE provides comprehensive CRISPR services to facilitate this research, from knockout and point mutation models to library screening and bioinformatics.
References
- 1. Inman GJ et al.. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.. Mol Pharmacol 62(1):65-74 PMID: 12065756
- 2. Massagué J et al.. 1992. TGF-beta receptors.. Mol Reprod Dev 32(2):99-104 PMID: 1322148
- 3. Wrana JL. 2000. Crossing Smads.. Sci STKE 2000(23):re1 PMID: 11752591
- 4. Zhen G et al.. 2013. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis.. Nat Med 19(6):704-12 PMID: 23685840
- 5. Brattain MG et al.. 1996. The type II transforming growth factor-beta receptor as a tumor-suppressor gene.. Curr Opin Oncol 8(1):49-53 PMID: 8868100
- 6. Horie K et al.. 1998. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.. J Cell Physiol 175(3):305-13 PMID: 9572475
- 7. Yakymovych I et al.. 2018. Intracellular trafficking of transforming growth factor β receptors.. Acta Biochim Biophys Sin (Shanghai) 50(1):3-11 PMID: 29186283
- 8. Zhang W et al.. 2009. Single-molecule imaging reveals transforming growth factor-beta-induced type II receptor dimerization.. Proc Natl Acad Sci U S A 106(37):15679-83 PMID: 19720988
